Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.53 |
| ▸ | RAF1 | P04049 | 4/20 | 0.50 |
| ▸ | SRC | P12931 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734976 | 0.89 | BRAF (0.54) | BRAFRAF1SRCJAK2CYP2C9 | |
| SCHEMBL13734640 | 0.88 | BRAF (0.55) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL13734662 | 0.82 | BRAF (0.53) | BRAFRAF1SRCCYP2C9YES1 | |
| SCHEMBL16195447 | 0.77 | BRPF1 (0.56) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL13735473 | 0.76 | BRAF (0.54) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL14481050 | 0.74 | JAK2 (0.86) | BRAFSRCJAK2JAK1MAPK14 | |
| SCHEMBL14819854 | 0.73 | BRAF (0.69) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL16195581 | 0.72 | BRAF (0.53) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL1697887 | 0.72 | BRAF (0.68) | BRAFRAF1CYP2C9YES1 | |
| SCHEMBL13736193 | 0.71 | BRAF (0.51) | BRAFRAF1CYP2C9YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | claimed |
| EP-2701507-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | claimed |
| WO-2012148792-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | claimed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2701507-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012148792-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323519-A1 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885SRC 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.